Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly (LLY) stock is higher Thursday after the pharmaceutical ... driven by demand for its weight-loss drugs, Mounjaro and Zepbound. Earnings per share (EPS) rose 113.7% from the year-ago ...

Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound ... by their 11.5% and 16% stock price drop, respectively ...

Shares of Eli Lilly and Co. slumped toward their biggest ... due to big misses in sales of anti-obesity drugs Mounjaro and Zepbound. The company said sales of Mounjaro and Zepbound were hurt ...

Diabetes treatment Mounjaro's sales more than triple and Zepbound's top $1.2 billion to beat expectations by 34% Shares of Eli Lilly ... to $43.6 billion. Lilly's stock has run up 43.1% year ...

Eli Lilly & Co. Inc.’s stock LLY rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study.

Eli Lilly's weight loss treatment Zepbound might ... Here, I discuss what this means for the company and the stock. Zepbound showed much promise in garnering revenues from the word go, since ...